TEMPUS

Comprehensive Profiles Requisition (NYS) 2025.09.08

p: 800.739.4137 | f: 800.893.0276 | e: support@tempus.com

Associated Study	Study ID

If any inf	ormation is incomplete or mis	sing, testing may be de	elayed.									
ORDERING PHYSICIAN II	NFORMATION											
Ordering Physician (full legal name)											NPI#	
Facility Name	Name Tempus Account #				Email (required for report delivery)				Fax			
Facility Address (Street, Unit)	eet, Unit) City					State		State	Postal (Code	Country	
Additional person to be copied					Form co	mpleted by					I.	
Name	Email/Fax	Facility Name			Name			Email/Fax			Facility Name	
PATIENT INFORMATION												
Last Name				MI		First Name						
DOB (MM/DD/YYYY)	Medical Record #	Biological Sex F M Un	ıknown	Email						Phone		
Address (Street, Unit)		<u> </u>	City				State	Pos	tal Code	Country		
BILLING INFORMATION												
Primary insurance plan name	Policy #				Group#			Policy Holde	r Name		Policy Hol	der DOB
Patient relationship to policy holder	: Self Spouse Child	Other:				Bill Typ	e: Insu	ırance Hos	pital/Instituti	on Sel	f pay/International	
CURRENT CANCER DIAGN	NOSIS											
Biliary	Colorectal	Heme	Pano	creatic	Primary	ICD-10 Codes (C	D & 7 coo	Joe).				
Bladder	Endometrial	Hepatocellular	Pros	state	Primary ICD-10 Codes (C, D, & Z codes): Disease Status (select all that apply): Metastatic, refractory, relapsed, or recurrent						1 -	
Breast	Esophageal	Melanoma	Rena	al						Stage:		
Cancer of Unknown Primary	Gastric	NSCLC		coma		vidence of Disease						
Cervical Central Nervous System	Head and Neck	Ovarian	Thyr Othe		Has the patient had any type of transplant? No Yes; Type:							
<u> </u>	riead and Neck	Ovarian	Othe	-1		1Athan and an			D fo t		OT fan turn an and a sur	d LDT for home
TESTING OPTIONS								_	DX JOF LUTTOF+	normai, Li	DT for tumor-only, an	a LDT for neme.
Comprehensive Therapy S	Selection 1					Individual Test Options						
xT (DNA) and tailored testing ac	dd-ons by current cancer diagr	nosis				SOLID TUMOR & HEME						
Liquid biopsy add-ons (select only	y one):					Tumor + Normal: xT (DNA) Reflex to xF ²						
Add xF concurrently						Tumor Only: xT (DNA) Heme: xT (DNA)						
Reflex to xF ²								xT (DNA)				
Hereditary add-ons:						XF	У Н	CancerNext-	Expanded® 3	Ca	ancerNext® 3	
Add CancerNext-Expanded® 3						Al .	L ₂	Add +RNA			Add +RNAinsight®	
+RNAinsight®						Add-on Tes	ts					
y managar						TISSUE-BASE						
1 Tempus uses the diagnosis information resources/ for tests ordered by current c		d by current cancer diagnosis	s. See <u>tempu</u>	ıs.com/testi	ng-	PD-L1 (22C3	3)	PD-L1 (28-8)	FC	DLR1 ³	MGMT ³
 Reflex to xF in the event xT results in QN Powered by a Tempus partner lab. 	S or no actionable variants.					PD-L1 (SP14 PD-L1 (SP26		HER2 + FISH MMR	I Reflex ³		.DN18 ³ MET ³	1p/19q ³
						. 5 22 (0. 20	-					
SPECIMEN RETRIEVAL					,,		See T	empus' specir	nen guideline	s for colled	ction instructions and	further details.
	Aspirate Submitting patholog				ails are no	1						
	gy Lab (Name, City) Specimen Collection Facility					Patient status at time of specimen collection: Office/Non-Hospital						
Case Number	Block #	# Date of Collection / Biopsy to be schedule				Hospital Outpatient Not yet discharged <i>OR</i> Discharge date:						
Blood / Saliva / Other												
Mobile phlebotomy Send saliva kit to patient Sample previously submitted					Patient status at time of specimen collection:							
Date of Collection: Specimen Collection Facility:					Hos	Office/Non-Hospital Hospital Outpatient → Not yet discharged <i>OR</i> Discharge date:						

PHYSICIAN SIGNATURE & CONSENT

Date of Collection:

My signature certifies that (1) the patient has received an explanation of the purpose, risks, and benefits of the ordered test(s); (2) the ordered test(s) are medically necessary and will inform the patient's treatment plan; (3) unless otherwise set forth on this form, the patient has recurrent, relapsed, refractory, metastatic, or advanced stages III or IV cancer; and (d) the patient has reviewed are shaped, (e) the order to esclose a recurrent patient has recurrent, relapsed, refractory, metastatic, or advanced stages III or IV cancer; and (d) the patient has provided informed consent that meets the requirements of applicable law for Tempus or rise reference lab to: (a) collect and use the patient's samples (including genetic material) and health information and perform the ordered test(s); (b) obtain, receive, and release health information (including test results) as necessary for reimbursement or the processing of insurance claims; (c) retain and use samples and health information for an indefinite period of time in accordance with applicable law; and (d) de-identify such samples and information and use and share the resulting de-identified samples and information in accordance with applicable law.

In addition, my signature certifies that if xT and xF are ordered within 30 days of one another, the order is medically necessary because guidelines support the use of testing, turnaround time for tissue result may delay a treatment decision, the tissue is at risk to fail (e.g. small tissue, archived tissue) and I may not have a timely result to make a treatment decision; and/or genomic heterogeneity may cause available tissue to not be completely representative, and I want to make sure I have a complete mutation profile.

Copy of patient's progress notes and/or medical records

Specimen Collection Facility:

Today's Date (MM/DD/YYYY): Ordering Physician Signature: Printed Name (full legal name):

Please also complete the required New York State patient consent form. If this form is not completed it may result in order delays.

Test Name	Description	Specimen(s) Required	Kit Type
xT CDx	FDA-approved 648-gene DNA sequencing test.	FFPE tissue and normal blood or saliva	Tempus Tissue ●, Blood ●, Saliva ●
xT LDT	648-gene DNA sequencing test.	FFPE tissue, or blood (EDTA), or bone marrow aspirate (EDTA)	Tempus Tissue ●, Heme ●
xF	105-gene liquid biopsy tests for solid tumors.	Blood (Streck)	Tempus Blood ●
CancerNext®	40-gene hereditary cancer tests , powered by Ambry Genetics.	Blood (EDTA) or saliva	Hereditary Blood (DNA), Hereditary Saliva (DNA)
CancerNext-Expanded®	77-gene hereditary cancer tests , powered by Ambry Genetics.	Blood (EDTA) or saliva	Hereditary Blood (DNA), Hereditary Saliva (DNA)
+RNAinsight®	Germline RNA sequencing add-on, powered by Ambry Genetics.	Blood (PAXgene®)	Hereditary Blood (DNA+RNA)

xT CDx logistical details: If a normal sample is timely provided, Tempus will run xT CDx for any xT test. If unavailable, Tempus will reflex to xT LDT. Refer to tempus.com/testing-resources for reflex protocols.

The following fields are for CancerNext® or CancerNext-Expanded® orders ONLY. Disregard if not testing for hereditary cancers.

RELEVANT CLINICAL HISTORY (Previous cancer diagnosis, GI polyps, etc.)							
FAMILY HISTORY							
None/No known family history	Unknown Adop	1					
Relationship to patient	Maternal	Paternal	Age at diagnosis	Details of relev	vant history		
ANCESTRY					BONE MARROW TRANSPLANT		
White/Caucasian	White/Caucasian Native American Middle Eastern				Personal history of allogeneic bone marrow or peripheral stem cell transplant: Yes No		
Hispanic	East Asian	Ashl	kenazi Jewish		Note: Using a blood or saliva sample is not appropriate for patients who have undergone an allogeneic bone		
Black/African American	South Asian	Othe	er:		marrow or peripheral stem cell transplant.		
PRIOR PERSONAL OR FAMILY HISTORY OF GENETIC TESTING					*For comments related to a prior test result, include the gene and variant (c. and/or p.) AND a test order ID or a copy of the result (required if external lab).		
No personal or family history of molecular and/or genetic testing.					Relationship to patient: Self Family member:		
Germline testing *					Microsatellite instability analysis:		
Test performed: Results:					Stable (MSS) Unstable/High (MSI-High) Unstable/Low (MSI-Low)		
Somatic/tumor testing *					Immunohistochemical staining		
Test performed:	Resu	lts:			Proteins present: Proteins absent:		